The development of pharmaceutical HIV prevention technologies (PPTs) over the last five years has generated intense interest from a range of stakeholders. There are concerns that these clinical and pharmaceutical interventions are proceeding with insufficient input of the social sciences. Hence key questions around implementation and evaluation remain unexplored whilst biomedical HIV prevention remains insufficiently critiqued or theorised from sociological as well as other social science perspectives. This paper presents the results of an expert symposium held in the UK to explore and build consensus on the role of the social sciences in researching and evaluating PPTs in this context. The symposium brought together UK social scientists fr...
This manuscript draws connections between chemoprophylaxis and the biomedical model of disease that ...
Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infectio...
This manuscript draws connections between chemoprophylaxis and the biomedical model of disease that ...
The development of pharmaceutical HIV prevention technologies (PPTs) over the last five years has ge...
The development of pharmaceutical HIV prevention technologies (PPTs) over the last five years has ge...
The development of pharmaceutical HIV prevention technologies (PPTs) over the last five years has ge...
The challenges of transferring biomedical advances and non-biomedical technological innovations in H...
Prevention with positives (PP) has occupied a central role in HIV prevention strategies since the in...
Here, we address the governance of the HIV and AIDS pandemic with reference to the social aspects of...
BACKGROUND: The fact that HIV prevention often deals with politicised sexual and drug taking behavio...
This article examines how biomedicalisation is encountered, responded to and negotiated within and i...
Background. Despite the evidence showing the promise of HIV treatment as prevention...
Objectives: There is a clear need to understand the factors that might prevent and/or facilitate the...
Evidence of the efficacy of HIV treatment as prevention (TasP) precipitated a highly optimistic glob...
This manuscript draws connections between chemoprophylaxis and the biomedical model of disease that ...
This manuscript draws connections between chemoprophylaxis and the biomedical model of disease that ...
Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infectio...
This manuscript draws connections between chemoprophylaxis and the biomedical model of disease that ...
The development of pharmaceutical HIV prevention technologies (PPTs) over the last five years has ge...
The development of pharmaceutical HIV prevention technologies (PPTs) over the last five years has ge...
The development of pharmaceutical HIV prevention technologies (PPTs) over the last five years has ge...
The challenges of transferring biomedical advances and non-biomedical technological innovations in H...
Prevention with positives (PP) has occupied a central role in HIV prevention strategies since the in...
Here, we address the governance of the HIV and AIDS pandemic with reference to the social aspects of...
BACKGROUND: The fact that HIV prevention often deals with politicised sexual and drug taking behavio...
This article examines how biomedicalisation is encountered, responded to and negotiated within and i...
Background. Despite the evidence showing the promise of HIV treatment as prevention...
Objectives: There is a clear need to understand the factors that might prevent and/or facilitate the...
Evidence of the efficacy of HIV treatment as prevention (TasP) precipitated a highly optimistic glob...
This manuscript draws connections between chemoprophylaxis and the biomedical model of disease that ...
This manuscript draws connections between chemoprophylaxis and the biomedical model of disease that ...
Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infectio...
This manuscript draws connections between chemoprophylaxis and the biomedical model of disease that ...